JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120487

Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor

Be the first to review this product! Submit a review

|

(22 Publications)

MW 467.5 Da, Purity >90%. Achieve your results faster with highly validated, pure and trusted compounds.
4 Images
Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)
  • FuncS

Unknown

Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)

HeLa cells were incubated at 37°C for 1h with vehicle control (0 μM) and different concentrations of Z-VAD(OMe)-FMK (ab120487). After this incubation 10 μM of camptothecin (ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLa cells correlates with an increase in Z-VAD(OMe)-FMK concentration, as described in literature.

Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 μg /ml and ab8227 at 1 μg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution.

Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)
  • FuncS

Lab

Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)

Titration of the Caspase inhibitor Z-VAD(OMe)-FMK (ab120487) (duplicates; +/- SD).

Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)
  • FuncS

Unknown

Functional Studies - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)

Functional assays : Caspase 3 (active) Red Staining Kit (ab65617)

Caspase 3 activity in Jurkat cells (3 x10e5 cells) following 24 hour exposure to 2 μM Camptothecin (ab120115) with or without 50 μM caspase inhibitor Z-VAD(OMe)-FMK (ab120487). Background signal subtracted, duplicates; +/- SD.

Chemical Structure - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)
  • Chemical Structure

Lab

Chemical Structure - Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor (AB120487)

2D chemical structure image of ab120487, Z-VAD(OMe)-FMK, Cell permeable, irreversible pan-caspase inhibitor

Key facts

CAS number

634911-81-2

Purity

>90%

Form

Solid

form

Molecular weight

467.5 Da

Molecular formula

C<sub>2</sub><sub>2</sub>H<sub>3</sub><sub>0</sub>FN<sub>3</sub>O<sub>7</sub>

PubChem

5497173

Nature

Synthetic

Solubility

Soluble in DMSO to 20 mM

Biochemical name

methyl 5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate

Canonical smiles

CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1

Isomeric smiles

C[C@@H](C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1

InChi

InChI=1S/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)/t14-,16?,19-/m0/s1

InChiKey

MIFGOLAMNLSLGH-SXUUOERCSA-N

IUPAC Name

methyl 5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Product protocols

Publications (22)

Recent publications for all applications. Explore the full list and refine your search

JCI insight 10: PubMed39932783

2025

Quantitative hypermorphic FAM111A alleles cause autosomal recessive Kenny-Caffey syndrome type 2 and osteocraniostenosis.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Li,Niels Mailand,Emma Ewing,Saskia Hoffmann,Richard C Caswell,Lewis Pang,Jacqueline Eason,Ying Dou,Kathleen E Sullivan,Hakon Hakonarson,Michael A Levine

Journal of biomedical science 31:33 PubMed38532423

2024

Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck.

Applications

Unspecified application

Species

Unspecified reactive species

I-Tsu Chyuan,Hsiu-Jung Liao,Tse-Hua Tan,Huai-Chia Chuang,Yu-Chuan Chu,Meng-Hsun Pan,Chien-Sheng Wu,Ching-Liang Chu,Bor-Ching Sheu,Ping-Ning Hsu

Life science alliance 6: PubMed37793778

2023

FAM111A regulates replication origin activation and cell fitness.

Applications

Unspecified application

Species

Unspecified reactive species

Diana O Rios-Szwed,Vanesa Alvarez,Luis Sanchez-Pulido,Elisa Garcia-Wilson,Hao Jiang,Susanne Bandau,Angus Lamond,Constance Alabert

Cell reports 41:111826 PubMed36543138

2022

BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Vijaya Bharti,Reese Watkins,Amrendra Kumar,Rebecca L Shattuck-Brandt,Alexis Mossing,Arjun Mittra,Chengli Shen,Allan Tsung,Alexander E Davies,Walter Hanel,John C Reneau,Catherine Chung,Gina M Sizemore,Ann Richmond,Vivian L Weiss,Anna E Vilgelm

The FEBS journal 290:1596-1624 PubMed36239430

2022

Early loss of endogenous NAD following rotenone treatment leads to mitochondrial dysfunction and Sarm1 induction that is ameliorated by PARP inhibition.

Applications

Unspecified application

Species

Unspecified reactive species

Ankita Sarkar,Sourav Dutta,Malinki Sur,Semanti Chakraborty,Puja Dey,Piyali Mukherjee

Frontiers in pharmacology 13:884821 PubMed36016572

2022

Neuronal MD2 induces long-term mental impairments in septic mice by facilitating necroptosis and apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Zhongmin Fan,Hongwei Ma,Yi Li,You Wu,Jiajia Wang,Lize Xiong,Zongping Fang,Xijing Zhang

Cell death & disease 13:662 PubMed35906211

2022

Hypoxia aggravates ferroptosis in RPE cells by promoting the Fenton reaction.

Applications

Unspecified application

Species

Unspecified reactive species

Yoshiyuki Henning,Ursula Sarah Blind,Safa Larafa,Johann Matschke,Joachim Fandrey

EMBO reports 21:e50662 PubMed32776417

2020

FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease.

Applications

Unspecified application

Species

Unspecified reactive species

Saskia Hoffmann,Satyakrishna Pentakota,Andreas Mund,Peter Haahr,Fabian Coscia,Marta Gallo,Matthias Mann,Nicholas Mi Taylor,Niels Mailand

Molecular & cellular proteomics : MCP 19:1236-1247 PubMed32357974

2020

Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.

Applications

Unspecified application

Species

Unspecified reactive species

Shutao Mei,Rochelle Ayala,Sri H Ramarathinam,Patricia T Illing,Pouya Faridi,Jiangning Song,Anthony W Purcell,Nathan P Croft

PLoS pathogens 16:e1008105 PubMed32092124

2020

Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Chandrima Gain,Samaresh Malik,Shaoni Bhattacharjee,Arijit Ghosh,Erle S Robertson,Benu Brata Das,Abhik Saha
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com